Overview
Australian clinical-stage biopharmaceutical company developing MDMA, psilocybin, and cannabis-derived therapeutics for mental health conditions with a data-driven clinical trial platform. They operate licensed clinics to generate real-world evidence for regulatory submissions.
More in Psychedelics
Latest industry news
FDA Grants De Novo Approval to Modius Spero Neuromodulation Device for PTSD
2026-09-23 · Policy
Vagus Nerve Stimulation Enters the Sports Performance Arena With New Anxiety Support Device
2026-09-22 · Product
Aurenar Raises $5.7M to Accelerate Stroke Neuromodulation Device Development
2026-09-21 · Funding
UCANACT Raises €800,000 to Advance Brain-Computer Communication Technology
2026-09-20 · Funding
Company details
Category
🍄 Psychedelics
Location
Perth, Australia
Funding
Public · ASX
Website
emyria.com.auListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →